PROMUS Element Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the TAXUS Element Coronary Stent System in Unselected Patients in Routine Clinical Practice.
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Thrombosis
- Focus Therapeutic Use
- Acronyms TE-Prove
- Sponsors Boston Scientific Corporation
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 24 Oct 2011 Additional locations (Belgium, England, France, Hungary, Ireland, Italy, Poland, Spain) added as reported by ClinicalTrials.gov.
- 24 Oct 2011 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov.